Losartan Cost in Pennsylvania 2026: Cash Prices, Medicaid, Insurance, and Savings Programs

What Does Losartan Actually Cost in Pennsylvania in 2026?

Generic losartan is one of the most affordable prescription drugs in Pennsylvania. The average cash price at Pennsylvania retail pharmacies sits near $10 per month for a standard 50 mg once-daily supply in 2026, and several discount programs push that figure to $4 or less at chains such as Walmart, Costco, and Giant Food Stores.

Merck's branded Cozaar carries a list price near $80 per month, but fewer than 5% of Pennsylvania patients pay that figure. The drug lost patent protection in 2010, and generic manufacturers now dominate the market. The FDA maintains a current list of approved losartan generics at FDA Orange Book [1].

Price variation across Pennsylvania is real. A GoodRx search for losartan 50 mg (30 tablets) in Philadelphia typically returns prices between $4 and $18, while rural central Pennsylvania pharmacies may show $9 to $22 before discount coupons apply. Using a free discount card (GoodRx, RxSaver, NeedyMeds) almost always closes that gap to under $12 statewide.

Pharmacies participating in the federal 340B Drug Pricing Program, including many Pennsylvania Federally Qualified Health Centers (FQHCs), can dispense losartan at deeply reduced prices to eligible low-income patients [2]. Patients who receive care at a 340B-covered site should ask the pharmacy counter directly about 340B pricing before paying cash.

The clinical rationale for losartan's widespread use is strong. The LIFE trial (N=9,193) published in The Lancet in 2002 demonstrated that losartan-based therapy reduced the composite of cardiovascular death, stroke, and myocardial infarction by 13% relative to atenolol-based therapy (RR 0.87 to 95% CI 0.77 to 0.98, P<0.021) in patients with hypertension and left ventricular hypertrophy [3]. That trial helped cement angiotensin receptor blockers (ARBs) as first-line antihypertensives in guideline recommendations from organizations including the American Heart Association [4].

Pennsylvania Medicaid Coverage for Losartan

Pennsylvania Medicaid (Medical Assistance) covers losartan on its preferred drug list for three indications: hypertension, heart failure, and diabetic nephropathy in patients with type 2 diabetes. No prior authorization is required for the generic 25 mg, 50 mg, or 100 mg tablets when prescribed within standard dosing ranges.

Pennsylvania's Medicaid program is administered through managed care organizations (MCOs) including Highmark Wholecare, UPMC Community HealthChoices, Geisinger Health Plan, and AmeriHealth Caritas. Each MCO must cover drugs on the Pennsylvania Preferred Drug List (PDL), and losartan is a preferred ARB on that list [5]. Cost-sharing for Medicaid enrollees is minimal. Most PA Medicaid beneficiaries pay $1 to $3 per prescription fill, and some categories, including pregnant patients and children, pay $0.

The FDA approved losartan for hypertension in 1995 and for nephropathy in patients with type 2 diabetes and elevated serum creatinine in 2001, based on the RENAAL trial (N=1,513), which showed a 16% reduction in the composite of doubling of serum creatinine, end-stage renal disease, or death compared to placebo (RR 0.84 to 95% CI 0.72 to 0.98, P<0.022) [6]. Pennsylvania Medicaid's coverage of losartan for diabetic nephropathy directly aligns with that FDA labeling [7].

Dual-eligible patients enrolled in both Medicare Part D and Pennsylvania Medicaid receive losartan through Part D with Extra Help (Low Income Subsidy), which caps copays at $4.50 for generic drugs in 2026 [8]. Pennsylvania's State Pharmaceutical Assistance Program (PACE/PACENET) provides additional help for seniors above Medicaid income thresholds; PACENET enrollees pay a $15 co-pay per generic fill [9].

Which Insurance Plans Cover Losartan in Pennsylvania?

Most commercial insurance plans sold in Pennsylvania cover generic losartan as a Tier 1 (preferred generic) drug. Tier 1 copays on ACA marketplace plans typically range from $0 to $15 per 30-day fill, though the exact amount depends on the specific plan's formulary [10].

Pennsylvania's largest commercial carriers, including Highmark, UPMC Health Plan, Independence Blue Cross, and Geisinger, all list generic losartan on their 2026 formularies as Tier 1. Branded Cozaar, when it appears at all, sits at Tier 3 or Tier 4, with copays of $45 to $90, making the generic the clear economic choice for nearly every insured patient.

For employer-sponsored insurance, a 2023 analysis by the Health Care Cost Institute found that the average patient cost-share for ARBs in commercial plans was $9.47 per 30-day fill [11]. Pennsylvania employer plans closely track that national benchmark.

Patients whose plans deny coverage or place losartan on a non-preferred tier have two tools. First, a formulary exception request, supported by a physician's letter citing clinical necessity, succeeds in a large proportion of ARB cases where the patient has a documented intolerance to ACE inhibitors (ACE inhibitor cough affects roughly 10 to 15% of patients) [12]. Second, a discount card price of $4 to $10 often beats the insured copay outright, and patients can choose to use the discount card and not bill insurance for that fill.

The 2024 JNC-aligned guidelines from the American College of Cardiology and American Heart Association continue to recommend ARBs, including losartan, as equivalent first-line agents to ACE inhibitors for hypertension management, particularly in patients with diabetes or chronic kidney disease [4].

Compounded Losartan in Pennsylvania: Legality and Access

Compounded losartan is legal in Pennsylvania through state-licensed 503A compounding pharmacies. It is not commercially available as a compound through 503B outsourcing facilities because losartan is not on the FDA's current drug shortage list, and 503B compounding is restricted to drugs meeting shortage or other specific criteria [13].

A 503A pharmacy compounds drugs for individual patients based on a valid prescriber-patient relationship. In Pennsylvania, 503A pharmacies are licensed and inspected by the Pennsylvania State Board of Pharmacy. A prescriber, including one working via a telehealth platform, can send a losartan compounding order to a licensed Pennsylvania 503A pharmacy for a specific patient [14].

Why would a patient use compounded losartan at all, given that commercial generic tablets cost $10 or less per month? Several reasons exist. Some telehealth-based care programs bundle compounded medications into a subscription fee, making the effective out-of-pocket cost $0 for the losartan component. Compounding also allows non-standard strengths (for example, 12.5 mg capsules for patients requiring dose titration below the 25 mg commercial minimum, or liquid formulations for patients with swallowing difficulties).

Patients should verify that any Pennsylvania 503A pharmacy they use is listed in active status on the Pennsylvania State Board of Pharmacy license lookup before filling a compound prescription [14]. Unlicensed compounders operate outside the law and do not meet FDA or state quality standards [13].

The table below outlines the key decision points a Pennsylvania prescriber and patient should work through when choosing between commercial generic losartan and a compounded formulation.

Choosing Commercial Generic vs. Compounded Losartan in Pennsylvania: Decision Framework

| Factor | Commercial Generic | Compounded 503A | |---|---|---| | Cost (cash pay) | ~$4 to $10/month | $0 to $15/month depending on program | | Medicaid billable | Yes | No (Medicaid does not cover compounds) | | Medicare Part D billable | Yes | No | | Available strengths | 25 mg, 50 mg, 100 mg tablets | Custom (e.g., 12.5 mg, liquid) | | Requires 503A pharmacy | No | Yes | | Patient needing non-standard dose | Second choice | First choice | | Telehealth-prescribable | Yes | Yes |

Telehealth Prescribing of Losartan in Pennsylvania

Telehealth prescribing of losartan is fully legal in Pennsylvania. The state lifted its pre-pandemic in-person visit requirement for non-controlled substances in 2020, and subsequent Pennsylvania legislation made that change permanent for drugs that are not Schedule II through V controlled substances [15].

Losartan is not a controlled substance. A Pennsylvania-licensed physician, physician assistant, or CRNP can initiate a losartan prescription after a synchronous audio-video visit, and many platforms now accept asynchronous (store-and-forward) visits for straightforward hypertension management following an initial synchronous evaluation.

The 2023 AHA/ACC Hypertension Guideline notes that remote blood pressure monitoring combined with telehealth prescribing produced blood pressure reductions comparable to in-person management in multiple randomized trials, supporting the clinical legitimacy of the telehealth pathway [4]. A 2022 JAMA Internal Medicine study (N=2,272) showed that patients receiving antihypertensive therapy through telehealth achieved target blood pressure (<130/80 mmHg) at rates statistically similar to in-person cohorts at 12 months [16].

Pennsylvania requires that any telehealth prescriber be licensed in Pennsylvania and that a valid prescriber-patient relationship exist prior to prescribing. Platforms operating across state lines must verify Pennsylvania licensure for every encounter [15].

Savings Programs Available to Pennsylvania Residents

Multiple overlapping programs can bring losartan cost to near zero for Pennsylvania patients who qualify.

GoodRx and Comparable Discount Cards. Free discount cards from GoodRx, RxSaver, and NeedyMeds are accepted at most Pennsylvania retail pharmacies and can reduce a 30-day losartan supply to $4 to $10. These cards are not insurance; they are negotiated discount agreements with pharmacy benefit managers. Any patient, regardless of income, can use them [17].

Merck's Patient Assistance Program. Merck offers the Merck Patient Assistance Program for uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). Qualifying patients may receive branded Cozaar at no cost, though the clinical rationale for choosing branded over generic is narrow given bioequivalence [18]. Generic manufacturers do not offer comparable patient assistance programs, but the low cash price makes one less necessary.

PACE and PACENET. Pennsylvania's Pharmaceutical Assistance Contract for the Elderly (PACE) covers Pennsylvanians aged 65 and older with incomes at or below $14,500 (single) or $17,700 (married) as of 2025, paying drug costs above a small co-pay. PACENET covers higher incomes (up to $27,500 single / $35,500 married) with a $15 generic co-pay. Both programs accept losartan claims [9].

NeedyMeds Drug Discount Card. The NeedyMeds card is free and provides discounts at over 70,000 pharmacies nationally, including all major Pennsylvania chains [17]. NeedyMeds also maintains a Patient Assistance Program database where Pennsylvania residents can search by drug name for manufacturer programs.

340B Program. Patients receiving primary care at Pennsylvania FQHCs, Ryan White HIV clinics, or qualifying rural health centers may access 340B pricing on losartan, which can bring cost to under $2 per fill [2].

County Assistance Offices. Pennsylvania residents who do not currently qualify for Medicaid but face a temporary financial hardship may apply at a County Assistance Office for emergency Medicaid coverage or for referral to county pharmaceutical assistance programs.

Dosing, Formulations, and What Pennsylvania Pharmacies Stock

Losartan is available as 25 mg, 50 mg, and 100 mg oral tablets. The standard starting dose for hypertension in adults is 50 mg once daily, with titration to 100 mg once daily if blood pressure remains above goal [7]. For diabetic nephropathy, the target dose studied in RENAAL was 100 mg once daily [6].

Pennsylvania retail pharmacies, including CVS, Rite Aid, Giant Food Stores, Walmart, and independent pharmacies, universally stock all three strengths of generic losartan. Supply chain disruptions affecting generic losartan have been uncommon since 2020, though the FDA's drug shortage database should be checked if a pharmacy reports a stock-out [19].

Losartan is also available as a fixed-dose combination tablet with hydrochlorothiazide (HCTZ) under the brand name Hyzaar, with generics widely available. The combination tablet at losartan 50 mg / HCTZ 12.5 mg costs approximately $12 to $20 per month on a discount card in Pennsylvania, making it a cost-effective option for patients requiring diuretic combination therapy [20].

A 2021 Cochrane review of ARBs for hypertension (84 trials, N=58,018) found that losartan at 50 to 100 mg once daily reduced systolic blood pressure by a mean of 8.3 mmHg and diastolic blood pressure by 5.3 mmHg versus placebo, with a tolerability profile superior to ACE inhibitors owing to the absence of ACE inhibitor-related cough [21]. That evidence base supports the AHA's classification of ARBs as first-line therapy [4].

Monitoring Requirements That Affect Ongoing Cost

Prescribers initiating or managing losartan in Pennsylvania patients should factor in monitoring lab costs, which affect total annual treatment cost even when the drug itself is inexpensive.

The AHA/ACC guideline recommends checking a basic metabolic panel (serum potassium, creatinine, and eGFR) at baseline, at 4 weeks after initiation or any dose change, and then every 6 to 12 months in stable patients [4]. Hyperkalemia is the primary electrolyte risk, occurring in roughly 2 to 4% of patients on ARB monotherapy and more commonly in patients with chronic kidney disease or those taking concomitant potassium-sparing diuretics [12].

In Pennsylvania, a basic metabolic panel at a commercial lab (Quest, LabCorp) costs $15 to $45 out-of-pocket before insurance. Medicaid and Medicare cover lab monitoring without additional patient cost-sharing in most cases [8]. Including two lab panels annually, the total annual cost of losartan therapy for an uninsured Pennsylvania patient using discount cards and standard labs falls in the range of $80 to $170 per year.

Pregnancy is an absolute contraindication. The FDA issued a black-box warning for all ARBs and ACE inhibitors noting that use during the second and third trimesters can cause fetal renal dysplasia, oligohydramnios, neonatal hypotension, and death [7]. Pennsylvania prescribers managing women of reproductive age on losartan should document pregnancy counseling at each visit and consider a negative urine pregnancy test before initiation per standard practice.

How Losartan Compares to Other Low-Cost ARBs Available in Pennsylvania

Losartan is not the only affordable ARB on Pennsylvania formularies. Valsartan, irbesartan, and olmesartan generics are similarly priced, generally $8 to $15 per month on discount cards [20]. Telmisartan generic costs slightly more, around $15 to $25 per month, owing to lower dispensing volume.

Among ARBs, losartan has the most extensive cardiovascular outcomes data, anchored by LIFE (N=9,193) [3] and RENAAL (N=1,513) [6]. It is also the only ARB with an FDA-approved indication specifically for reducing stroke risk in hypertensive patients with left ventricular hypertrophy, a finding driven by the LIFE trial result [3].

For patients with chronic kidney disease and proteinuria who have no heart failure, the 2022 KDIGO Clinical Practice Guideline for Diabetes Management in CKD recommends an ARB or ACE inhibitor as first-line, citing RENAAL and IDNT trial data, and lists losartan as the reference ARB given the depth of its evidence base [22].

Pennsylvania's Medicaid preferred drug list does not impose a step-therapy requirement favoring one ARB over another for most indications, meaning a prescriber can initiate losartan directly without requiring failure of a different ARB first [5].